229 related articles for article (PubMed ID: 22107041)
1. In vitro study of antiadipogenic profile of latanoprost, travoprost, bimatoprost, and tafluprost in human orbital preadiopocytes.
Choi HY; Lee JE; Lee JW; Park HJ; Lee JE; Jung JH
J Ocul Pharmacol Ther; 2012 Apr; 28(2):146-52. PubMed ID: 22107041
[TBL] [Abstract][Full Text] [Related]
2. Deepening of the upper eyelid sulcus caused by 5 types of prostaglandin analogs.
Inoue K; Shiokawa M; Wakakura M; Tomita G
J Glaucoma; 2013; 22(8):626-31. PubMed ID: 22936280
[TBL] [Abstract][Full Text] [Related]
3. Changes to upper eyelid orbital fat from use of topical bimatoprost, travoprost, and latanoprost.
Park J; Cho HK; Moon JI
Jpn J Ophthalmol; 2011 Jan; 55(1):22-7. PubMed ID: 21331688
[TBL] [Abstract][Full Text] [Related]
4. Comparative efficacy and tolerability of topical prostaglandin analogues for primary open-angle glaucoma and ocular hypertension.
Lin L; Zhao YJ; Chew PT; Sng CC; Wong HT; Yip LW; Wu TS; Bautista D; Teng M; Khoo AL; Lim BP
Ann Pharmacother; 2014 Dec; 48(12):1585-93. PubMed ID: 25184309
[TBL] [Abstract][Full Text] [Related]
5. Prostaglandin associated periorbitopathy in patients using bimatoprost, latanoprost and travoprost.
Kucukevcilioglu M; Bayer A; Uysal Y; Altinsoy HI
Clin Exp Ophthalmol; 2014 Mar; 42(2):126-31. PubMed ID: 23844550
[TBL] [Abstract][Full Text] [Related]
6. Adverse periocular reactions to five types of prostaglandin analogs.
Inoue K; Shiokawa M; Higa R; Sugahara M; Soga T; Wakakura M; Tomita G
Eye (Lond); 2012 Nov; 26(11):1465-72. PubMed ID: 23037910
[TBL] [Abstract][Full Text] [Related]
7. Blood-aqueous barrier changes after the use of prostaglandin analogues in patients with pseudophakia and aphakia: a 6-month randomized trial.
Arcieri ES; Santana A; Rocha FN; Guapo GL; Costa VP
Arch Ophthalmol; 2005 Feb; 123(2):186-92. PubMed ID: 15710814
[TBL] [Abstract][Full Text] [Related]
8. Ocular surface tolerability of prostaglandin analogs in patients with glaucoma or ocular hypertension.
Whitson JT; Trattler WB; Matossian C; Williams J; Hollander DA
J Ocul Pharmacol Ther; 2010 Jun; 26(3):287-92. PubMed ID: 20578283
[TBL] [Abstract][Full Text] [Related]
9. Hyperemia-associated costs of medication changes in glaucoma patients treated initially with prostaglandin analogs.
Schwartz GF; Tan J; Kotak S
J Ocul Pharmacol Ther; 2009 Dec; 25(6):555-61. PubMed ID: 20028264
[TBL] [Abstract][Full Text] [Related]
10. Latanoprost therapy after sunken eyes caused by travoprost or bimatoprost.
Nakakura S; Tabuchi H; Kiuchi Y
Optom Vis Sci; 2011 Sep; 88(9):1140-4. PubMed ID: 21666524
[TBL] [Abstract][Full Text] [Related]
11. Mechanism and clinical significance of prostaglandin-induced iris pigmentation.
Stjernschantz JW; Albert DM; Hu DN; Drago F; Wistrand PJ
Surv Ophthalmol; 2002 Aug; 47 Suppl 1():S162-75. PubMed ID: 12204714
[TBL] [Abstract][Full Text] [Related]
12. Human trabecular meshwork cell responses induced by bimatoprost, travoprost, unoprostone, and other FP prostaglandin receptor agonist analogues.
Sharif NA; Kelly CR; Crider JY
Invest Ophthalmol Vis Sci; 2003 Feb; 44(2):715-21. PubMed ID: 12556403
[TBL] [Abstract][Full Text] [Related]
13. Eyelash growth induced by topical prostaglandin analogues, bimatoprost, tafluprost, travoprost, and latanoprost in rabbits.
Giannico AT; Lima L; Russ HH; Montiani-Ferreira F
J Ocul Pharmacol Ther; 2013 Nov; 29(9):817-20. PubMed ID: 23981234
[TBL] [Abstract][Full Text] [Related]
14. Agonist activity of bimatoprost, travoprost, latanoprost, unoprostone isopropyl ester and other prostaglandin analogs at the cloned human ciliary body FP prostaglandin receptor.
Sharif NA; Kelly CR; Crider JY
J Ocul Pharmacol Ther; 2002 Aug; 18(4):313-24. PubMed ID: 12222762
[TBL] [Abstract][Full Text] [Related]
15. Conjunctival hyperaemia with the use of latanoprost versus other prostaglandin analogues in patients with ocular hypertension or glaucoma: a meta-analysis of randomised clinical trials.
Honrubia F; García-Sánchez J; Polo V; de la Casa JM; Soto J
Br J Ophthalmol; 2009 Mar; 93(3):316-21. PubMed ID: 19019922
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and tolerability of bimatoprost versus travoprost in patients previously on latanoprost: a 3-month, randomised, masked-evaluator, multicentre study.
Kammer JA; Katzman B; Ackerman SL; Hollander DA
Br J Ophthalmol; 2010 Jan; 94(1):74-9. PubMed ID: 19726422
[TBL] [Abstract][Full Text] [Related]
17. Activation of the prostanoid FP receptor inhibits adipogenesis leading to deepening of the upper eyelid sulcus in prostaglandin-associated periorbitopathy.
Taketani Y; Yamagishi R; Fujishiro T; Igarashi M; Sakata R; Aihara M
Invest Ophthalmol Vis Sci; 2014 Mar; 55(3):1269-76. PubMed ID: 24508785
[TBL] [Abstract][Full Text] [Related]
18. Conjunctival hyperemia in healthy subjects after short-term dosing with latanoprost, bimatoprost, and travoprost.
Stewart WC; Kolker AE; Stewart JA; Leech J; Jackson AL
Am J Ophthalmol; 2003 Mar; 135(3):314-20. PubMed ID: 12614748
[TBL] [Abstract][Full Text] [Related]
19. The effects of prostaglandin analogues on IOP in prostanoid FP-receptor-deficient mice.
Ota T; Aihara M; Narumiya S; Araie M
Invest Ophthalmol Vis Sci; 2005 Nov; 46(11):4159-63. PubMed ID: 16249494
[TBL] [Abstract][Full Text] [Related]
20. The comparison of the effects of latanoprost, travoprost, and bimatoprost on central corneal thickness.
Zhong Y; Shen X; Yu J; Tan H; Cheng Y
Cornea; 2011 Aug; 30(8):861-4. PubMed ID: 21499083
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
